Marksans Pharma Limited

16%

N D C E O www.marksanspharma.com “Q2FY26 has been a strong quarter for us, with revenues growing 16% sequentially, driven by robust demand across our key markets. The US region recorded solid growth

44%

demand and delivered stable results despite continued pricing pressures. Our EBITDA and PAT grew 44% and 70% quarter-on-quarter, reflecting the benefits of operating leverage. Looking ahead, we rema

70%

nd delivered stable results despite continued pricing pressures. Our EBITDA and PAT grew 44% and 70% quarter-on-quarter, reflecting the benefits of operating leverage. Looking ahead, we remain optim

₹ 720

ent growth and long-term value for our stakeholders.” 6 2 Y F 2 Q 6 2 Y F 1 H Operating Revenue ₹ 720 cr Operating Revenue ₹ 1,341 cr EBITDA ₹ 144 cr EBITDA Margin 20.1% PAT ₹ 99 cr EBITDA ₹ 245

₹ 1,341

e for our stakeholders.” 6 2 Y F 2 Q 6 2 Y F 1 H Operating Revenue ₹ 720 cr Operating Revenue ₹ 1,341 cr EBITDA ₹ 144 cr EBITDA Margin 20.1% PAT ₹ 99 cr EBITDA ₹ 245 cr EBITDA Margin 18.2% PAT ₹

₹ 144

ers.” 6 2 Y F 2 Q 6 2 Y F 1 H Operating Revenue ₹ 720 cr Operating Revenue ₹ 1,341 cr EBITDA ₹ 144 cr EBITDA Margin 20.1% PAT ₹ 99 cr EBITDA ₹ 245 cr EBITDA Margin 18.2% PAT ₹ 157 cr Page 5

20.1%

Y F 1 H Operating Revenue ₹ 720 cr Operating Revenue ₹ 1,341 cr EBITDA ₹ 144 cr EBITDA Margin 20.1% PAT ₹ 99 cr EBITDA ₹ 245 cr EBITDA Margin 18.2% PAT ₹ 157 cr Page 5 Financial Highligh

₹ 99

rating Revenue ₹ 720 cr Operating Revenue ₹ 1,341 cr EBITDA ₹ 144 cr EBITDA Margin 20.1% PAT ₹ 99 cr EBITDA ₹ 245 cr EBITDA Margin 18.2% PAT ₹ 157 cr Page 5 Financial Highlights Q2FY26 –

₹ 245

₹ 720 cr Operating Revenue ₹ 1,341 cr EBITDA ₹ 144 cr EBITDA Margin 20.1% PAT ₹ 99 cr EBITDA ₹ 245 cr EBITDA Margin 18.2% PAT ₹ 157 cr Page 5 Financial Highlights Q2FY26 – QoQ Performance

18.2%

enue ₹ 1,341 cr EBITDA ₹ 144 cr EBITDA Margin 20.1% PAT ₹ 99 cr EBITDA ₹ 245 cr EBITDA Margin 18.2% PAT ₹ 157 cr Page 5 Financial Highlights Q2FY26 – QoQ Performance Q2FY26 Q1FY26 QoQ Gro

₹ 157

cr EBITDA ₹ 144 cr EBITDA Margin 20.1% PAT ₹ 99 cr EBITDA ₹ 245 cr EBITDA Margin 18.2% PAT ₹ 157 cr Page 5 Financial Highlights Q2FY26 – QoQ Performance Q2FY26 Q1FY26 QoQ Growth % QoQ Pe

₹ 720.4

ancial Highlights Q2FY26 – QoQ Performance Q2FY26 Q1FY26 QoQ Growth % QoQ Performance Revenue ₹ 720.4 cr ₹ 620.0 cr 16.2% Gross Profit Gross Margin ₹ 411.8 cr 57.2% ₹ 358.2 cr 57.8% 15.0% •

“ACC R ED I TAT I ON S Unit 2 in Goa Acquired Manufacturing facility in Goa • Scalable capacity with a plan to double the existing Indian capacity from 8bn units per annum • Manufacturing site is spread across 47,597 sq.”

“• Plan to manufacture tablets, ointments, liquids and creams ACC R ED I TAT I ON S www.marksanspharma.com *Acquired facility in Goa has scalable capacity to 8bn units p.a.”

“SKUs growth of ~75% to 1500+ Note: All numbers as of FY25 *Acquired facility in Goa has scalable capacity to 8bn units p.a.”

“Aim to capture a significant part of the multi-billion-dollar OTC opportunity.”

“• Our OTC segment grew at CAGR of 21% (from FY17-FY25) • Marksans is the most preferred and growing low-cost store brand manufacturing partner Innovation & Pipeline Power • Continued focus on R&D leading to a strong product pipeline and successful launches • Strong pipeline of more than 100 products Scale capacity and operating leverage • Aim to expanding capacity , scale the acquired unit in Goa, capacity to 8bn units p.a.”

Product approvals

1

Total Capacity

1

For more information please contact

1

Product approvals

UK, Relonchem: Received marketing authorization for – i) Metformin Hydrochloride Relonchem 500 mg, 750 mg & 1000 mg prolonged release tablets ii) Moxonidine 200 mg & 400 mg tablets iii) Clonidine 100 mg tablets & Clonidine Hydrochloride 25 mg tablets iv) Exemestane 25mg film-coated tablets www.marksanspharma.com Page 9 Revenue by Segment and Geography FY25 Revenue by Segment Rx 25.9% Q2 FY26 Revenue by Geography US & North America ₹ 387.3 cr 27% YoY UK & Europe ₹ 245.3 cr 1% YoY 53.8% 34.1% OTC 74.1% OTC Rx Our OTC segment grew at a CAGR of 21% (from FY17 to FY25) www.marksanspharma.com 3.7% RoW - ₹ 26.5 cr 4% YoY 8.5% Australia & New Zealand ₹ 61.3 cr 4% YoY Page 10 Quarterly Financial Trends Operating Revenue (₹ cr) Gross Profit (₹ cr) & Gross Margin (%) 682 709 642 720 620 384 384 383 59.7% 56.2% 54.1% 412 57.2% 358 57.8% 430 410 390 370 350 330 310 290 270 250 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 EBITDA (₹ cr) & EBITDA Margin (%) Net Income (₹ cr) &

Total Capacity

26 bn units p.a.* Manufacturing Facility in Southport, UK • Manufactures non-sterile liquids, ointments and powder sachets • Supplies to UK, West Africa & Middle East • Spread across 7,300 sq. mt. C A PAC I T Y 2 bn bottles p.a. 1 bn tubes p.a. 1 bn sachets p.a. ACC R ED I TAT I ON S Unit 2 in Goa Acquired Manufacturing facility in Goa • Scalable capacity with a plan to double the existing Indian capacity from 8bn units per annum • Manufacturing site is spread across 47,597 sq. mt. • Plan to manufacture tablets, ointments, liquids and creams ACC R ED I TAT I ON S www.marksanspharma.com *Acquired facility in Goa has scalable capacity to 8bn units p.a. Page 19 R&D Capabilities R&D (₹ cr) and R&D % to sales 0.6% 0.6% 1.5% 0.7% 1.4% 2.0% 1.6% 1.6% 2.2% 2.0% 58 30 29 35 26 15 8 5 5 19 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 H1FY26 Southport, United Kingdom Farmingdale, United States Navi Mumbai, India Goa, India R&D Centers Continued focus on R&D investments leading to a robust pipelin

For more information please contact

Jitendra Sharma (CFO) Marksans Pharma Ltd. Tel: +91 22 4001-2000 jitendra@marksanspharma.com Corporate Office 11th Floor Grandeur, Off Veera Desai Road, Opp Gundecha Symphony, Andheri (W), Mumbai – 400 053, Maharashtra - India www.marksanspharma.com © 2025 Marksans Pharma Ltd., All Rights Reserved. “Marksans Pharma” and The Marksans Pharma Logo are trademarks of Marksans Pharma Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.